References

Recent insights into the genetics of inflammatory bowel disease

10.1053/j.gastro.2011.02.046 · 2011 · External reference

Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease

10.1038/nature11582 · 2012 · External reference

The global burden of IBD: from 2015 to 2025

10.1038/nrgastro.2015.150 · 2015 · External reference

EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain

10.1177/1756284819847034 · 2019 · External reference

Gut microbiota and IBD: causation or correlation

10.1038/nrgastro.2017.88 · 2017 · External reference

The intestinal epithelial barrier: a therapeutic target

10.1038/nrgastro.2016.169 · 2017 · External reference

Cytokines in inflammatory bowel disease

10.1038/nri3661 · 2014 · External reference

STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the IOIBD

10.1053/j.gastro.2020.12.031 · 2021 · External reference

Biologic therapies in inflammatory bowel disease

10.1016/j.trsl.2014.01.002 · 2014 · External reference

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

10.1016/s0140-6736(02)08512-4 · 2002 · External reference

Vedolizumab as induction and maintenance therapy for ulcerative colitis

10.1056/nejmoa1215734 · 2013 · External reference

Ustekinumab as induction and maintenance therapy for Crohn's disease

10.1056/nejmoa1602773 · 2016 · External reference

Risankizumab: mechanism of action, clinical and translational science

10.1111/cts.13706 · 2024 · External reference

Tofacitinib as induction and maintenance therapy for ulcerative colitis

10.1056/nejmc1707500 · 2017 · External reference

Ozanimod: a review in ulcerative colitis

10.1007/s40265-022-01762-8 · 2022 · External reference

Remission rates achievable by current therapies for inflammatory bowel disease

10.1111/j.1365-2036.2011.04599.x · 2011 · External reference

Maintenance of clinical remission with biologics and small molecules in inflammatory bowel disease according to trial design: meta-analysis

10.1016/j.dld.2023.06.009 · 2024 · External reference

Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study

10.1136/gutjnl-2012-303376 · 2014 · External reference

Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet

10.1136/gutjnl-2024-332919 · 2025 · External reference

Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: the next frontier

10.1016/j.jaci.2018.10.015 · 2018 · External reference

Regulatory T cells and their role in inflammatory bowel disease: molecular targets, therapeutic strategies and translational advances

10.1016/j.bcp.2025.117087 · 2025 · External reference

Enhancing regulatory T cells to treat inflammatory and autoimmune diseases

10.3390/ijms24097797 · 2023 · External reference

CAR-T regulatory (CAR-Treg) cells: engineering and applications

10.3390/biomedicines10020287 · 2022 · External reference

From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases

10.3389/fimmu.2024.1509956 · 2024 · External reference

Regulatory CAR-T cells in autoimmune diseases: progress and current challenges

10.3389/fimmu.2022.934343 · 2022 · External reference

Antigen-specific therapeutic approaches for autoimmunity

10.1038/s41587-019-0015-4 · 2019 · External reference

Antigen-specific immunotherapies in rheumatic diseases

10.1038/nrrheum.2017.107 · 2017 · External reference

Engineered cellular immunotherapies in cancer and beyond

10.1038/s41591-022-01765-8 · 2022 · External reference

TCR-engineered T cell therapy in solid tumors: state of the art and perspectives

10.1126/sciadv.adf3700 · 2023 · External reference

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

10.1136/bmj.n71 · 2021 · External reference

Regulatory T cells and immune tolerance

10.1016/j.cell.2008.05.009 · 2008 · External reference

How regulatory T cells work

10.1038/nri2343 · 2008 · External reference

The inhibitory cytokine IL-35 contributes to regulatory T-cell function

10.1038/nature06306 · 2007 · External reference

IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy

10.1002/eji.200322919 · 2003 · External reference

CTLA-4 control over Foxp3+ regulatory T cell function

10.1126/science.1160062 · 2008 · External reference

Inducible costimulator (ICOS) is a marker for highly suppressive antigen-specific T cells sharing features of TH17/TH1 and regulatory T cells

10.1016/j.jaci.2010.05.022 · 2010 · External reference

Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self

10.1038/ni1178 · 2005 · External reference

Type 1 T regulatory cells

10.1034/j.1600-065x.2001.1820105.x · 2001 · External reference

Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells

10.1038/nm.3179 · 2013 · External reference

The microbiota regulates type 2 immunity through RORγt+ T cells

10.1126/science.aac4263 · 2015 · External reference

Individual intestinal symbionts induce a distinct population of RORγ+ regulatory T cells

10.1126/science.aaa9420 · 2015 · External reference

In vivo equilibrium of proinflammatory IL-17+ and regulatory IL-10+ Foxp3+ RORgamma t+ T cells

10.1084/jem.20080034 · 2008 · External reference

Regulatory T cells reinforce intestinal homeostasis

10.1016/j.immuni.2009.08.011 · 2009 · External reference

Disrupted regulatory T cell homeostasis in inflammatory bowel diseases

10.3748/wjg.v22.i3.974 · 2016 · External reference

Precursors for nonlymphoid-tissue treg cells reside in secondary lymphoid organs and are programmed by the transcription factor BATF

10.1016/j.immuni.2019.12.002 · 2020 · External reference

T regulatory cells in inflammatory bowel disease-are they major players

10.3390/ijms262411944 · 2025 · External reference

Th17/Treg imbalance in inflammatory bowel disease: immunological mechanisms and microbiota-driven regulation

10.3389/fimmu.2025.1651063 · 2025 · External reference

Type 1 diabetes immunotherapy using polyclonal regulatory T cells

10.1126/scitranslmed.aad4134 · 2015 · External reference

Administration of CD4+CD25highCD127- regulatory T cells preserves β-cell function in type 1 diabetes in children

10.2337/dc12-0038 · 2012 · External reference

Adoptive Treg cell therapy in a patient with systemic lupus erythematosus

10.1002/art.40737 · 2019 · External reference

First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells

10.1016/j.clim.2009.06.001 · 2009 · External reference

Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics

10.1182/blood-2010-07-293795 · 2011 · External reference

Protocol for a first-in-human feasibility study of T regulatory cells (TR004) for inflammatory bowel disease using (ex vivo) Treg expansion (TRIBUTE)

10.1136/bmjopen-2024-092733 · 2025 · External reference

Safety and tolerability of a single infusion of autologous ex vivo expanded regulatory T cells in adults with ulcerative colitis (ER-TREG 01): protocol of a phase 1, open-label, fast-track dose-escalation clinical trial

10.1136/bmjopen-2021-049208 · 2021 · External reference

Novel autologous regulatory T-cell therapy ameliorates DSS-induced colitis in humanized mice

10.1093/ibd/izaf141 · 2025 · External reference

CD150high bone marrow Tregs maintain hematopoietic stem cell quiescence and immune privilege via adenosine

10.1016/j.stem.2018.01.017 · 2018 · External reference

Transfer of bone marrow niche-residential regulatory T cells ameliorates experimental colitis

10.1016/j.cellimm.2025.104952 · 2025 · External reference

Regulatory T cell therapy promotes TGF-β and IL-6-dependent pro-inflammatory Th17 cell generation by reducing IL-2

10.1038/s41467-025-62628-7 · 2025 · External reference

Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease

10.1053/j.gastro.2012.07.116 · 2012 · External reference

Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis

10.1136/gutjnl-2022-327075 · 2023 · External reference

Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease

10.1136/gutjnl-2014-306919 · 2016 · External reference

Characterization and expansion of autologous GMP-ready regulatory T cells for TREG-based cell therapy in patients with ulcerative colitis

10.1097/mib.0000000000001192 · 2017 · External reference

Chimeric antigen receptor therapy

10.1056/nejmra1706169 · 2018 · External reference

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

10.1056/nejmoa1709866 · 2018 · External reference

Strategies to address chimeric antigen receptor tonic signaling

10.1158/1535-7163.mct-17-1097 · 2018 · External reference

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors

10.1073/pnas.90.2.720 · 1993 · External reference

Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes

10.1084/jem.188.4.619 · 1998 · External reference

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells

10.1182/blood-2013-10-535245 · 2014 · External reference

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

10.1056/nejmoa1103849 · 2011 · External reference

Clinical use of lentiviral vectors

10.1038/s41375-018-0106-0 · 2018 · External reference

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

10.1038/s41571-019-0297-y · 2020 · External reference

Armored human CAR Treg cells with PD1 promoter-driven IL-10 have enhanced suppressive function

10.1126/sciadv.adx7845 · 2025 · External reference

The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer

10.1038/s41571-025-01115-w · 2026 · External reference

CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multi-site retrospective cohort review

10.1182/bloodadvances.2025018604 · 2026 · External reference

Outcomes of tisagenlecleucel versus allogeneic hematopoietic stem cell transplantation in relapsed or refractory large B-cell lymphoma

10.1016/j.jcyt.2025.102028 · 2025 · External reference

Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM

10.1182/bloodadvances.2025019303 · 2026 · External reference

Successful spontaneous pregnancies and healthy neonates after dual-target CAR-T cell therapy in systemic lupus erythematosus

10.1002/art.70070 · 2026 · External reference

Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases

10.1038/s41591-025-04191-8 · 2026 · External reference

A novel approach to refractory idiopathic inflammatory myopathy: CD19 CAR T-cell therapy—case report and literature review

10.1093/rheumatology/keaf190 · 2025 · External reference

CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series

10.1016/s2665-9913(24)00282-0 · 2025 · External reference

Disappearance of antiphospholipid antibodies after anti-CD19 chimeric antigen receptor T-cell therapy of B-cell lymphoma in a patient with systemic lupus erythematosus and antiphospholipid syndrome

10.1016/j.jtha.2024.09.024 · 2025 · External reference

CD19 CAR T-cell therapy for autoimmune hemolytic anemia

10.1056/nejmoa2509820 · 2026 · External reference

Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells

10.1038/mt.2014.41 · 2014 · External reference

Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor

10.1053/j.gastro.2009.01.049 · 2009 · External reference

Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice

10.1053/j.gastro.2008.02.060 · 2008 · External reference

Flagellin-specific human CAR Tregs for immune regulation in IBD

10.1016/j.jaut.2022.102961 · 2023 · External reference

Bacterial flagellin is a dominant antigen in Crohn disease

10.1172/jci20295 · 2004 · External reference

Crohn's patients and healthy infants share immunodominant B cell response to commensal flagellin peptide epitopes

10.1053/j.gastro.2024.08.015 · 2024 · External reference

Crohn's disease patients uniquely contain inflammatory responses to flagellin in a CD4 effector memory subset

10.1093/ibd/izac146 · 2022 · External reference

IL23R-specific CAR Tregs for the treatment of Crohn's disease

10.1093/ecco-jcc/jjae135 · 2025 · External reference

CD19 CAR T-cell therapy in multidrug-resistant ulcerative colitis

10.1056/nejmc2508023 · 2025 · External reference

B cells in inflammatory bowel disease

10.1016/j.imlet.2025.107071 · 2026 · External reference

The yin and yang of B cells in a constant state of battle: intestinal inflammation and inflammatory bowel disease

10.3389/fimmu.2023.1260266 · 2023 · External reference

Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis

10.1136/gut.2010.225482 · 2011 · External reference